Kite (Santa Monica, CA), a Gilead company, has announced it has received approval to implement a variation to the Yescarta® (axicabtagene ciloleucel) Marketing Authorization from the European Medicines Agency (EMA) for end-to-end manufacturing. With this approval, the company reports, Kite’s European manufacturing facility, designed and dedicated to the manufacture of individualized cell therapies, is now fully operational. The European facility is located next to Amsterdam Airport Schiphol (The Netherlands) and has the capacity to produce therapy for up to 4,000 patients per year. Kite invested €130 million ($150 million) over just two years to transform the 19,000 square meter site, which employs over 300 people. Christi Shaw, Chief Executive Officer of Kite, said the facility “will benefit both patients and healthcare professionals, allowing axicabtagene ciloleucel to reach European treatment centres more quickly and reducing the time it takes to reach patients by almost a week.” Marie José Kersten, M.D., Ph.D., of Amsterdam University Medical Centers, added, “Timely access to cell therapy is critical, and the ability to manufacture CAR T cell therapies in Europe is welcomed by the clinical community.”
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.